publication venue for
- Embedding patients' values and preferences in guideline development for allergic diseases: The case study of Allergic Rhinitis and its Impact on Asthma 2024. 14:e12377. 2024
- Digitally‐enabled, patient‐centred care in rhinitis and asthma multimorbidity: The ARIA‐MASK‐air®approach. 13:e12215. 2023
- Real‐world data using mHealth apps in rhinitis, rhinosinusitis and their multimorbidities. 12:e12208. 2022
- Allergen immunotherapy in MASK‐air users in real‐life: Results of a Bayesian mixed‐effects model. 12:e12128. 2022
- Peanut allergy: Beyond the oral immunotherapy plateau. 11:e12046. 2021
- ARIA‐EAACI care pathways for allergen immunotherapy in respiratory allergy. 11:e12014. 2021
- Allergen immunotherapy for respiratory allergy: Quality appraisal of observational comparative effectiveness studies using the REal Life Evidence AssessmeNt Tool. An EAACI methodology committee analysis. 11:e12033. 2021
- Correction to: Is diet partly responsible for differences in COVID-19 death rates between and within countries?. 10:44. 2020
- Is diet partly responsible for differences in COVID-19 death rates between and within countries?. 10:16. 2020
- Nrf2-interacting nutrients and COVID-19: time for research to develop adaptation strategies. 10:58. 2020
- Treatment of allergic rhinitis during and outside the pollen season using mobile technology. A MASK study. 10:62. 2020
- Guidance to 2018 good practice: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma. 9:16. 2019
- Next-generation ARIA care pathways for rhinitis and asthma: a model for multimorbid chronic diseases. 9:44. 2019
- Interleukin-25 and eosinophils progenitor cell mobilization in allergic asthma. 8:5. 2018
- MASK 2017: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma multimorbidity using real-world-evidence. 8:45. 2018
- The Allergic Rhinitis Clinical Investigator Collaborative (AR-CIC): verification of nasal allergen challenge procedures in a study utilizing an investigational immunotherapy for cat allergy. 8:15. 2018
- Erratum to: Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3: Area 5). 7:5. 2017
- Abstracts from the 3rd International Severe Asthma Forum (ISAF). 7:14. 2017
- ARIA 2016: Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle. 6:47. 2016
- Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3: Area 5). 6:29. 2016
- 7th drug hypersensitivity meeting: part one. 6:31. 2016
- The hidden burden of adult allergic rhinitis: UK healthcare resource utilisation survey. 5:39. 2015
- PD16 ‐ Prevalence of childhood food allergy in Canada: a focus on under‐represented populations. 4:p16-p16. 2014
- Two year persistent treatment effect in reducing nasal symptoms of cat allergy after 4 doses of Cat‐PAD, the first in a new class of synthetic peptide immuno‐regulatory epitopes. 3:o7-o7. 2013
- The prevalence of food allergy among Aboriginal people in Canada. 3:p77-p77. 2013
- Two year persistent treatment effect in reducing nasal symptoms of cat allergy after 4 doses of Cat-PAD, the first in a new class of synthetic peptide immuno-regulatory epitopes. 3:O7-O7. 2013
- New perspectives on immunological pathways underlying peanut-induced anaphylaxis. 1:s68-s68. 2011
- Oral immunotherapy be heated ovomuciod-reduced egg white in a Balb/C mouse model. 1:O35-O35. 2011